[Treatment of acute bacterial meningitis: present and future].
Parras
F
F
Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid.
D000328:Adult; D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D001433:Bacteriolysis; D001929:Brain Edema / Q000209:etiology / Q000517:prevention & control; D018821:CD18 Antigens / Q000276:immunology; D002648:Child; D003131:Combined Modality Therapy; D005544:Forecasting; D006801:Humans; D008353:Mannitol / Q000627:therapeutic use; D016920:Meningitis, Bacterial / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D051379:Mice; D010403:Penicillin Resistance; D010672:Phenytoin / Q000627:therapeutic use; D013030:Spain / Q000453:epidemiology
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D018821:CD18 Antigens; D008353:Mannitol; D010672:Phenytoin
Tratamiento de la meningitis bacteriana aguda: presente y futuro.